| Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? | Lancet Respiratory Medicine | 2 hours | save |  |  |  |  |
| Monitoring the COVID-19 epidemic in the context of widespread local transmission | Lancet Respiratory Medicine | 1 day | save | | | | |
| β-blockade in sepsis: regulation of persisting sepsis-related tachycardia | Lancet Respiratory Medicine | 2 days | save | | | | |
| Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial | Lancet Respiratory Medicine | 2 days | save | | | | |
| COVID-19 infection in children | Lancet Respiratory Medicine | 7 days | save | | | | |
| Antihypertensive drugs and risk of COVID-19? – Authors' reply | Lancet Respiratory Medicine | 8 days | save | | | | |
| Antihypertensive drugs and risk of COVID-19? | Lancet Respiratory Medicine | 8 days | save | | | | |
| Antihypertensive drugs and risk of COVID-19? | Lancet Respiratory Medicine | 8 days | save | | | | |
| Efforts escalate to protect homeless people from COVID-19 in UK | Lancet Respiratory Medicine | 8 days | save | | | | |
| Antihypertensive drugs and risk of COVID-19? | Lancet Respiratory Medicine | 8 days | save | | | | |
| The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions | Lancet Respiratory Medicine | 9 days | save | | | | |
| Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies | Lancet Respiratory Medicine | 10 days | save | | | | |
| Can perturbations in microbial maturation cause asthma? | Lancet Respiratory Medicine | 10 days | save | | | | |
| Tackling two pandemics: a plea on World Tuberculosis Day | Lancet Respiratory Medicine | 10 days | save | | | | |
| Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases | Lancet Respiratory Medicine | 13 days | save | | | | |
| Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial | Lancet Respiratory Medicine | 13 days | save | | | | |
| Rational use of face masks in the COVID-19 pandemic | Lancet Respiratory Medicine | 13 days | save | | | | |
| Respiratory syncytial virus treatment and the respiratory microbiome | Lancet Respiratory Medicine | 13 days | save | | | | |
| COVID-19 outbreak: less stethoscope, more ultrasound | Lancet Respiratory Medicine | 13 days | save | | | | |
| Treatment for severe acute respiratory distress syndrome from COVID-19 | Lancet Respiratory Medicine | 13 days | save | | | | |
| Immunotherapy in lung cancer: effective for patients with poor performance status? | Lancet Respiratory Medicine | 14 days | save | | | | |
| Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial | Lancet Respiratory Medicine | 14 days | save | | | | |
| Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis | Lancet Respiratory Medicine | 18 days | save | | | | |
| Evolving therapies for rifampicin-resistant tuberculosis: balancing efficacy and toxicity | Lancet Respiratory Medicine | 18 days | save | | | | |
| COVID-19: the need for continuous medical education and training | Lancet Respiratory Medicine | 18 days | save | | | | |
| COVID-19: delay, mitigate, and communicate | Lancet Respiratory Medicine | 18 days | save | | | | |
| COVID-19, ECMO, and lymphopenia: a word of caution | Lancet Respiratory Medicine | 21 days | save | | | | |
| Blood transcriptional signatures for tuberculosis testing | Lancet Respiratory Medicine | 21 days | save | | | | |
| The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study | Lancet Respiratory Medicine | 21 days | save | | | | |
| COPD exacerbations: finally, a more than ACCEPTable risk score | Lancet Respiratory Medicine | 21 days | save | | | | |
| Blood transcriptional biomarkers for active pulmonary tuberculosis in a high-burden setting: a prospective, observational, diagnostic accuracy study | Lancet Respiratory Medicine | 21 days | save | | | | |
| Limited use of biomarker-guided therapy in mild asthma | Lancet Respiratory Medicine | 22 days | save | | | | |
| Sex difference and smoking predisposition in patients with COVID-19 | Lancet Respiratory Medicine | 22 days | save | | | | |
| Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial | Lancet Respiratory Medicine | 22 days | save | | | | |
| Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? | Lancet Respiratory Medicine | 22 days | save | | | | |
| Respiratory disease and Ramadan | Lancet Respiratory Medicine | 22 days | save | | | | |
| Adoption of COVID-19 triage strategies for low-income settings | Lancet Respiratory Medicine | 22 days | save | | | | |
| Discovery of lung cancer after an injury on holiday | Lancet Respiratory Medicine | 25 days | save | | | | |
| Surviving the ICU is only the beginning of a long road ahead | Lancet Respiratory Medicine | 25 days | save | | | | |
| Progress in the treatment of pulmonary fibrosis | Lancet Respiratory Medicine | 28 days | save | | | | |
| Respiratory support for patients with COVID-19 infection | Lancet Respiratory Medicine | 28 days | save | | | | |
| Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial | Lancet Respiratory Medicine | 28 days | save | | | | |
| Gag clause prevents discussion of assisted dying in Victoria, Australia | Lancet Respiratory Medicine | 32 days | save | | | | |
| Correction to Lancet Respir Med 2020; published online Feb 21. https://doi.org/10.1016/S2213-2600(20)30079-5 | Lancet Respiratory Medicine | 35 days | save | | | | |
| Systemic sclerosis-associated interstitial lung disease | Lancet Respiratory Medicine | 36 days | save | | | | |
| Challenges in evidence-based therapy for systemic sclerosis associated interstitial lung disease | Lancet Respiratory Medicine | 36 days | save | | | | |
| Programmatic versus personalised approaches to managing the global epidemic of multidrug-resistant tuberculosis | Lancet Respiratory Medicine | 36 days | save | | | | |
| Host-directed therapies and holistic care for tuberculosis | Lancet Respiratory Medicine | 36 days | save | | | | |
| Tuberculosis in children, adolescents, and women | Lancet Respiratory Medicine | 36 days | save | | | | |
| Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial | Lancet Respiratory Medicine | 37 days | save | | | | |
| | 
report | next » |
| |
